Overview
Metachromatic leukodystrophy (MLD) is a fatal, progressive neurodegenerative disorder caused by biallelic pathogenic mutations in the ARSA (Arylsulfatase A) gene, leading to impaired degradation of sulfatides and GM1 ganglioside 1.Diagnosis
Genetic Testing: Essential for confirming ARSA gene mutations 1.
Biochemical Testing: Arylsulfatase A enzyme activity measurement in leukocytes or fibroblasts 1.
Newborn Screening: Recommended to accelerate diagnosis and timely intervention 1.Management
Early Intervention: Critical for improved clinical outcomes; ex vivo gene therapy considered for presymptomatic patients in early onset MLD 1.
Specialist Care: Longitudinal management by specialists familiar with MLD 1.
No Specific Drug Doses Mentioned: Current management focuses on supportive care and emerging therapies like gene therapy 1.Special Populations
Pediatrics: Early diagnosis and intervention are paramount for better outcomes 1.
Pregnancy: No specific guidelines provided in the abstracts 1.
Elderly: Not specifically addressed in the provided abstracts 1.
Comorbidities: Management considerations for comorbidities not detailed in the abstracts 1.Key Recommendations
Diagnosis Should Include Both Genetic and Biochemical Testing: Essential for accurate identification of MLD 1 (Evidence: Strong).
Early Diagnosis and Treatment Improve Clinical Outcomes: Early intervention is crucial for better prognosis 1 (Evidence: Strong).
Development of Newborn Screening Programs: To expedite diagnosis and treatment initiation 1 (Evidence: Expert opinion).
Consider Ex Vivo Gene Therapy for Presymptomatic Early Onset MLD Patients: Recommended for improving outcomes in early stages 1 (Evidence: Moderate).References
1 Adang LA, Bonkowsky JL, Boelens JJ, Mallack E, Ahrens-Nicklas R, Bernat JA et al.. Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. Cytotherapy 2024. link
2 Ameen M, Chang PL. Pseudo arylsulfatase A deficiency. Biosynthesis of an abnormal arylsulfatase A. FEBS letters 1987. link81204-8)
3 Inui K, Kao FT, Fujibayashi S, Jones C, Morse HG, Law ML et al.. The gene coding for a sphingolipid activator protein, SAP-1, is on human chromosome 10. Human genetics 1985. link
4 Bach G, Neufeld EF. Synthesis and maturation of cross-reactive glycoprotein in fibroblasts deficient in arylsulfatase A activity. Biochemical and biophysical research communications 1983. link91816-8)
5 Fluharty AL, Meek WE, Kihara H. Pseudo arylsulfatase A deficiency: evidence for a structurally altered enzyme. Biochemical and biophysical research communications 1983. link91815-6)